Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aluminum hydroxide suspension Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

NCT04368585
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 24, 2026, 1:56 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162
View directory record Official record
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 4 Interventional Results available

Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

NCT00679302
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Trimethoprim-sulfamethoxazole, Placebo group
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

NCT03783130
View directory record Official record
Conditions
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions
VRC-HIVRGP096-00-VP, Alum Adjuvant
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults

NCT01717950
View directory record Official record
Conditions
Hookworm Infection, Hookworm Disease
Interventions
Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

NCT04915768
View directory record Official record
Conditions
HIV Infections
Interventions
CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

NCT03382418
View directory record Official record
Conditions
HIV Infections
Interventions
gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

NCT02143518
View directory record Official record
Conditions
Hookworm Infection, Hookworm Disease
Interventions
Na-GST-1/Alhydrogel®, CpG 10104
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

NCT04177355
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

NCT03049488
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
VRC-RSVRGP084-00-VP, Aluminum Hydroxide Suspension
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 24, 2026, 1:56 PM EDT
Suspended Phase 1 Interventional

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

NCT06680479
View directory record Official record
Conditions
HIV-1
Interventions
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 24, 2026, 1:56 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

NCT06267872
View directory record Official record
Conditions
HIV
Interventions
CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

NCT03589768
View directory record Official record
Conditions
Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis, Tetanus, Tetanus Immunisation
Interventions
Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

NCT03879603
View directory record Official record
Conditions
Venezuelan Equine Encephalitis, Western Equine Encephalitis, Eastern Equine Encephalitis, Alphavirus Infections
Interventions
VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 24, 2026, 1:56 PM EDT
Terminated Phase 4 Interventional

Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

NCT03490396
View directory record Official record
Conditions
Oral Mucositis
Interventions
Gelclair, First® Mouthwash BLM
Device · Combination Product
Lead sponsor
Midatech Pharma US Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 24, 2026, 1:56 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

NCT06796686
View directory record Official record
Conditions
HIV
Interventions
426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant, Aluminum hydroxide suspension (Alum) adjuvant, Diluent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 24, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

NCT03934541
View directory record Official record
Conditions
HIV Infections
Interventions
MPER-656 Liposome Vaccine, Placebo for MPER-656 Liposome Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 24, 2026, 1:56 PM EDT